Biography for Emily Mullin
Emily Mullin, Associate Editor
Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at firstname.lastname@example.org and follow her on Twitter at @EmilyMFierce.
- Contact Emily
- Follow Emily on Google+
Articles by Emily Mullin
The National Institutes of Health has forged 7 research agreements with academic and industry partners aimed at identifying new adjuvant candidates that could be used in vaccines to boost immune responses against various pathogens.
Soligenix won a grant for up to $24.7 million from the U.S. National Institutes of Health to advance its thermostabilization technology, ThermoVax, in combination with the company's ricin toxin vaccine, RiVax, as a medical countermeasure to prevent the effects of ricin exposure.
Another vaccine hopeful is joining the fight against Ebola. Inovio Pharmaceuticals said this week that it will move its Ebola vaccine candidate into clinical trials in the first half of 2015.
CureVac has made its second notable deal with Big Pharma this year, this time partnering with Boehringer Ingelheim to offer its investigational lung cancer vaccine in a $45 million deal with potential milestone payments of up to $556 million.
Asterias Biotherapeutics, a subsidiary of California-based BioTime, is teaming up with nonprofit Cancer Research UK to trial an immunotherapy vaccine to treat patients with non-small cell lung cancer.
As the death toll of West Africa's Ebola outbreak reaches 2,500, GlaxoSmithKline's experimental Ebola vaccine is being tested at the U.S. National Institutes of Health with no apparent ill effects so far, health officials report.
Ebola vaccine research is moving ahead at lightening speed thanks to combined public and private sector efforts, with GlaxoSmithKline unveiling fresh data showing that its experimental jab protected monkeys in a preclinical study.
A new breast cancer vaccine tested in a clinical trial at the University of Texas MD Anderson Cancer Center boosted survival rates in patients with elevated levels of a protein associated with cancer growth, a new study shows.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
Looking back on data from old pediatric HIV vaccine trials, researchers have found that two vaccines studied in the 1990s elicited a specific antibody response that was unknown at the time to be associated with HIV protection.